An Investigation into the Preparation, Characterization, and Therapeutic Applications of Novel Gefitinib/Capric Acid Deep Eutectic Systems

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmaceutical Innovation Pub Date : 2024-11-28 DOI:10.1007/s12247-024-09884-0
Faisal Al-Akayleh, Bayan Alkhawaja, Mayyas Al-Remawi, Nizar Al-Zoubi, Jehad Nasereddin, Tim Woodman,  Nisrein Jaber, Mohammad IA. Ahmad, Luay AbuQatouseh, Derar Omari, Ahmed S. A. Ali Agha
{"title":"An Investigation into the Preparation, Characterization, and Therapeutic Applications of Novel Gefitinib/Capric Acid Deep Eutectic Systems","authors":"Faisal Al-Akayleh,&nbsp;Bayan Alkhawaja,&nbsp;Mayyas Al-Remawi,&nbsp;Nizar Al-Zoubi,&nbsp;Jehad Nasereddin,&nbsp;Tim Woodman,&nbsp; Nisrein Jaber,&nbsp;Mohammad IA. Ahmad,&nbsp;Luay AbuQatouseh,&nbsp;Derar Omari,&nbsp;Ahmed S. A. Ali Agha","doi":"10.1007/s12247-024-09884-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>In this work, we sought to report and fully characterise novel therapeutic deep eutectic systems (THEDESs) formed between Gefitinib (Gef) and capric acid (CA). In addition, we will study the impact of this formulation on solubility and therapeutic efficacy.</p><h3>Methods</h3><p>The THEDES were formed using a simple preparation method. Gef and CA were mixed in increasing molar ratios of CA at 40 °C. A phase diagram was used to identify an optimal molar ratio for eutectic formation. Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and NMR were used to characterise the eutectic systems. Lastly, Cytotoxicity assessments on EGFR-expressing cell lines were conducted to evaluate the therapeutic efficacy of the formulations.</p><h3>Results</h3><p>According to the phase diagram, the optimal molar ratio of Gef: CA was found to be G2 (80:20), which facilitates the formation of a homogeneous liquid system at room temperature, confirmed by DSC. FTIR and NMR analysis revealed significant shifts in specific peaks, indicating hydrogen bonding between Gef and CA. More specifically, a downfield shift was observed at protons adjacent to the tertiary nitrogen of the morpholine ring. Gef solubility in CA was enhanced considerably, 30,000 times higher than in aqueous solutions at pH 5. Lastly, according to the cytotoxicity tests, THEDESs, particularly G2 and G3 formulations, have significantly reduced IC50 values compared to individual components, demonstrating a synergistic effect.</p><h3>Conclusions</h3><p>The work reports the novel THEDESs of Gef and CA, which enhance Gef solubility and exhibit a synergistic cytotoxic effect against EGFR-expressing cell lines. These findings suggest that THEDESs could offer a promising and facile approach for improving the solubility and therapeutic efficacy of poorly soluble drugs.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-024-09884-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

In this work, we sought to report and fully characterise novel therapeutic deep eutectic systems (THEDESs) formed between Gefitinib (Gef) and capric acid (CA). In addition, we will study the impact of this formulation on solubility and therapeutic efficacy.

Methods

The THEDES were formed using a simple preparation method. Gef and CA were mixed in increasing molar ratios of CA at 40 °C. A phase diagram was used to identify an optimal molar ratio for eutectic formation. Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and NMR were used to characterise the eutectic systems. Lastly, Cytotoxicity assessments on EGFR-expressing cell lines were conducted to evaluate the therapeutic efficacy of the formulations.

Results

According to the phase diagram, the optimal molar ratio of Gef: CA was found to be G2 (80:20), which facilitates the formation of a homogeneous liquid system at room temperature, confirmed by DSC. FTIR and NMR analysis revealed significant shifts in specific peaks, indicating hydrogen bonding between Gef and CA. More specifically, a downfield shift was observed at protons adjacent to the tertiary nitrogen of the morpholine ring. Gef solubility in CA was enhanced considerably, 30,000 times higher than in aqueous solutions at pH 5. Lastly, according to the cytotoxicity tests, THEDESs, particularly G2 and G3 formulations, have significantly reduced IC50 values compared to individual components, demonstrating a synergistic effect.

Conclusions

The work reports the novel THEDESs of Gef and CA, which enhance Gef solubility and exhibit a synergistic cytotoxic effect against EGFR-expressing cell lines. These findings suggest that THEDESs could offer a promising and facile approach for improving the solubility and therapeutic efficacy of poorly soluble drugs.

Graphical Abstract

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型吉非替尼/己二酸深度共晶体系的制备、表征和治疗应用研究
目的在这项工作中,我们试图报告吉非替尼(Gef)和癸酸(CA)之间形成的新型治疗深共晶体系(THEDES),并对其进行全面鉴定。此外,我们还将研究这种配方对溶解度和疗效的影响。Gef 和 CA 在 40 °C 下以 CA 的摩尔比递增的方式混合。利用相图确定共晶形成的最佳摩尔比。使用差示扫描量热法(DSC)、傅立叶变换红外光谱法(FTIR)和核磁共振法对共晶体系进行表征。最后,对表达表皮生长因子受体的细胞系进行了细胞毒性评估,以评价制剂的疗效:根据相图,Gef:CA 的最佳摩尔比为 G2(80:20),这有助于在室温下形成均匀的液体体系,这一点已得到 DSC 的证实。傅立叶变换红外光谱(FTIR)和核磁共振(NMR)分析表明,特定峰值发生了显著变化,表明 Gef 和 CA 之间存在氢键。更具体地说,与吗啉环的叔氮相邻的质子发生了下场移动。最后,根据细胞毒性测试,THEDESs,尤其是 G2 和 G3 配方,与单个成分相比,IC50 值显著降低,显示出协同效应。这些研究结果表明,THEDESs 可为改善溶解性差的药物的溶解度和疗效提供一种前景广阔的简便方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
期刊最新文献
The Assessment of Vaginal permeability – in silico Approach Coconut Oil and Shea Butter as Lipids for the Formulation of Ciprofloxacin-Loaded Nanoparticles Ezetimibe Loaded Nanostructured Lipid Carriers Tablets: Response Surface Methodology, In-vitro Characterization, and Pharmacokinetics Study in Rats Advanced Normal-Phase HPTLC Profiling of Eltrombopag Olamine with Automated Development and Box-Behnken Optimizations Characterization of Thermoresponsive Poly(N-vinylcaprolactam) Polymer Containing Doxorubicin-Loaded Niosomes: Synthesis, Structural Properties, and Anticancer Efficacy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1